Cercare Medical is excited to announce our continued participation at Neurorad 2026, taking place 7–9 October in Mainz, Germany.
As a frontrunner in the field of perfusion imaging, we are proud to support Neurorad and its continued focus on advancing neuroradiological diagnostics, intervention, and emerging technologies.
With Neurorad highlighting the next generation of neuroradiology, what better way to showcase the future of stroke treatment than by introducing the next generation of perfusion imaging: Cone-Beam CT Perfusion.
Cone-Beam CT (CBCT) Perfusion brings CT-quality perfusion imaging - along with Cercare Medical’s unique oxygen-metabolism biomarkers in the angio suite using the standard C-arm systems already in place. For the first time, interventional teams can assess tissue health and viability in real time, at the point of treatment.
Discover how Cone-Beam CT Perfusion can be integrated with syngo DynaCT Multiphase on the Siemens Healthineers ARTIS icono family. The solution extends the capabilities of Cercare Medical Neurosuite into the angio suite, providing advanced perfusion imaging to support clinicians during image-guided stroke treatment.
We will also be showcasing Cercare Medical Neurosuite (CMN), our flagship solution for advanced perfusion imaging and quantitative analysis across CT, CBCT, and MR.
CMN supports efficient stroke workflows through fully automated perfusion processing, providing standardized and reproducible maps and quantitative biomarkers, including:
Visit us for live demonstrations of our latest perfusion and AI imaging solutions. Our team will be available throughout the event to discuss your clinical or research needs.
See you in Mainz!
Cercare Medical is a provider of advanced perfusion imaging solutions. With fully automated and multi-vendor compatible software for CT, CBCT, and MRI perfusion imaging post-processing, we are committed to delivering cutting-edge technology that enhances patient care and advances medical diagnostics across various neurological conditions, including Stroke, Oncology, Alzheimer's, Dementia, and COVID-19. Our proprietary biomarkers allow for better, more precise imaging maps, improving decision-making in critical care and enhancing neuroimaging. This innovative technology has led to widespread adoption by leading hospitals and clinics around the world.